1. India Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Arvee Laboratories (India) Ltd.

Arvee Laboratories (India) Ltd.

ARVEE.NS
Arvee Laboratories (India) Ltd.IN flagNational Stock Exchange of India
160.35
INR
-0.08
- -
1.77BMarket Cap
Arvee Laboratories (India) Ltd.
ARVEE.NS
(National Stock Exchange of India)

Recent

price

160.35

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.24
14.52
15.96
33.01
41.91
55.05
48.96
40.69
55.31
36.02
55.6
27.53
34.88
25.12
Revenue per Share
0.05
0.02
-2.03
0.23
1.91
1.29
2.05
2.09
3.14
2.34
3.74
0.95
1.95
1.92
Basic EPS, GAAP
0.63
-8.11
3.6
1.98
3.08
5.55
7.22
7.28
-0.68
-1.53
1.31
0.98
-1.87
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.06
3.69
3.69
4.98
5.17
8.01
8.18
10.27
22.88
19.97
23.71
24.66
26.61
- -
Book Value per Share
0.11
3.77
1.74
3.25
5.17
16.85
14.9
16.99
25.12
21.71
25.46
26.42
28.37
- -
Tangible Book Value per Share
8
8
8
8
8
8
11
11
9
11
11
11
11
11
Basic Weighted Avg Shares
34
118
130
268
341
464
540
448
471
397
613
303
384
271
Sales/Revenue/Turnover
5.54
13.76
10.63
13.13
11.33
10.89
7.21
8.56
8.08
7.56
8.55
4.9
6.41
4.25
Operating Margin (%)
- -
2
7
15
21
22
24
24
25
24
21
15
12
12
Depreciation Expense
- -
- -
-16
2
16
11
23
23
27
26
41
11
21
21
Net Income, GAAP
19.02
18.97
- -
65.02
- -
43.15
11.05
25.61
26.48
25.38
33.19
42.51
25.2
31.07
Effective Tax Rate (%)
1.25
0.16
-12.7
0.7
4.56
2.35
4.19
5.13
5.68
6.48
6.72
3.47
5.59
7.65
Profit Margin (%)
40
15
28
34
39
60
48
54
73
89
127
99
158
- -
Working Capital
73
80
153
174
166
79
35
20
10
10
10
10
10
- -
LT Debt
1
31
14
26
42
142
165
188
214
239
281
291
313
- -
Total Equity
- -
11.05
- -
4.91
- -
9.65
11.6
10.95
10.52
7.77
12.43
2.89
5.9
5.59
Return on Invested Capital (%)
- -
8.01
- -
4.71
- -
10.63
15.82
15.98
13.95
10.5
16.49
4.19
7.72
-2.51
Return on Capital (%)
- -
1.23
-54.9
5.32
37.6
19.88
28.7
22.62
17.38
12.4
17.12
3.95
7.6
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
- -
10
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
11
- -
Market Capitalization
1,971
1,674
2,302

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
- -
241
- -
Cash, Cash Equivalents & STI
- -
69
- -
Accounts Receivable, Net
- -
24
- -
Inventories
- -
115
- -
Total Current Liabilities
- -
68
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.78%
10.86%
7.38%
Free Cash Flow
-25.11%
-83.9%
-291.12%
Net Income, GAAP
79.85%
20.46%
104.15%
Sales/Revenue/Turnover
18.93%
3.98%
26.68%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
76
89
77
61
303
2025
106
125
89
64
384
2026
75
35
98
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.44
0.19
0.22
- -
0.95
2025
0.85
0.89
0.14
- -
1.95
2026
0.15
0.01
1.66
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Binani Industries Limited (BINANIIND.BO)
Transpek Industry Limited (TRANSPEK.BO)
Lanxess AG (LNXSF)
KBC Corporation, Ltd. (688598.SS)
POVAL KOGYO Co., Ltd. (4247.T)
CFOAM Limited (CFO.AX)
Business
Arvee Laboratories (India) Ltd. Arvee Laboratories (India) Ltd. manufactures and sells specialized chemicals primarily in the specialty chemicals sector, focusing on polymer modifiers, contrast media intermediates, and drug intermediates for industrial, pharmaceutical, and medical imaging applications. The company produces polymer modifiers including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(β-hydroxyethyl)-isophthalate; contrast media intermediates such as 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, dimethyl 5-aminoisophthalate, 3,5-dinitrobenzoic acid, and 3,5-diamino benzoic acid; and drug intermediates comprising 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4-amino pyridine, and 2-chloro-5-nitrobenzoic acid. Incorporated in 2012 and headquartered at 403, Entice Building, Ahmedabad, Gujarat, India, Arvee Laboratories (India) Ltd. operates with approximately 65 employees and exports its products internationally to markets including pharmaceutical manufacturers in India, the United States, and Europe. Recent developments include the appointment of Saurin Gandhi as additional director and chief financial officer effective August 12, 2025; the resignation of whole-time director Shalin Bharatbhai Chokshi effective June 30, 2025; approval of Q1 FY26 results and scheduling of the 13th annual general meeting for September 24, 2025; and submission of the annual report for FY2024-25.